Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | THRB | P10828 | 1/20 | 0.50 |
| ▸ | IDO1 | P14902 | 1/20 | 0.50 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.46 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.46 |
| ▸ | GFER | P55789 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24847549 | 1.00 | CYP1A2 (0.54) | CYP1A2LMNAPTGS2CYP2C9CYP2C19 | |
| SCHEMBL4748433 | 0.87 | CYP2C19 (0.53) | CYP1A2LMNAPTGS2CYP2C9CYP2C19 | |
| SCHEMBL28445772 | 0.83 | TRPA1 (0.47) | CYP1A2LMNAPTGS2CYP2D6SMN1; SMN2 | |
| SCHEMBL3068166 | 0.83 | CYP1A2 (0.48) | CYP1A2LMNAPTGS2CYP2C9CYP2C19 | |
| SCHEMBL4418820 | 0.83 | LMNA (0.51) | CYP1A2LMNAPTGS2CYP2C9CYP2C19 | |
| SCHEMBL4123487 | 0.83 | SMN1; SMN2 (0.56) | LMNATHRBSMN1; SMN2NPC1RAB9A | |
| Pivhydrazine SCHEMBL149084 | 0.82 | SMN1; SMN2 (0.57) | CYP1A2LMNAPTGS2CYP2C9CYP2C19 | |
| SCHEMBL8843835 | 0.82 | ALDH1A1 (0.66) | LMNAGAAKMT2AMEN1TRPV1 | |
| SCHEMBL8843411 | 0.81 | ALDH1A1 (0.59) | LMNASMN1; SMN2RAB9AGAAEPHX2 | |
| SCHEMBL13738026 | 0.81 | L3MBTL1 (0.50) | LMNAGAAKMT2AMEN1FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12600699-B2 | Thiosemicarbazates and uses thereof | THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) | 2026-04-14 | — | — | US | disclosed |
| US-12595233-B2 | Thiosemicarbazates and uses thereof | THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) | 2026-04-07 | — | — | US | disclosed |
| US-20260091009-A1 | ROLES OF MODULATORS OF INTERSECTIN-CDC42 SIGNALING IN ALZHEIMER'S DISEASE | Lu, Qun (US) | 2026-04-02 | — | — | US | disclosed |
| US-12285393-B2 | Roles of modulators of intersectin-Cdc42 signaling in Alzheimer's disease | Lu, Qun (US) | 2025-04-29 | — | — | US | disclosed |
| EP-3814348-B9 | SUBSTITUTED NAPHTHYRIDINONE COMPOUNDS USEFUL AS T CELL ACTIVATORS | BRISTOL MYERS SQUIBB CO (US) | 2023-11-01 | — | — | EP | disclosed |
| EP-3814348-B1 | SUBSTITUTED NAPHTHYRIDINONE COMPOUNDS USEFUL AS T CELL ACTIVATORS | BRISTOL MYERS SQUIBB CO (US) | 2023-08-02 | — | — | EP | disclosed |
| US-11713316-B2 | Substituted naphthyridinone compounds useful as T cell activators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-08-01 | — | — | US | disclosed |
| US-20230165815-A1 | ROLES OF MODULATORS OF INTERSECTIN-CDC42 SIGNALING IN ALZHEIMER?S DISEASE | Lu, Qun (US) | 2023-06-01 | — | — | US | disclosed |
| US-20230111252-A1 | THIOSEMICARBAZATES AND USES THEREOF | THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) | 2023-04-13 | — | — | US | disclosed |
| CN-115698035-A | Inhibitors of norovirus and coronavirus replication | 共晶制药公司 | 2023-02-03 | — | — | CN | disclosed |
| US-5708002-A | ASCOMYCIN ANALOGS, IMMUNOSUPPRESSANTS | ABBOTT LABORATORIES (US) | 1998-01-13 | — | — | US | disclosed |
| US-5561228-A | IMMUNOSUPPRESSNATS; SIDE EFFECT REDUCTION | ABBOTT LABORATORIES (US) | 1996-10-01 | — | — | US | disclosed |
| US-5457111-A | Side effect reduction | ABBOTT LABORATORIES (US) | 1995-10-10 | — | — | US | disclosed |
| EP-0642516-A1 | MACROCYCLIC IMMUNOMODULATORS | ABBOTT LABORATORIES (US) | 1995-03-15 | — | — | EP | disclosed |
| CN-1100090-A | amine derivatives of oxo-and hydroxy-substituted hydrocarbons | NARHEX LTD (HK) | 1995-03-15 | — | — | CN | disclosed |
| EP-0638082-A1 | MACROCYCLIC IMMUNOMODULATORS | ABBOTT LABORATORIES (US) | 1995-02-15 | — | — | EP | disclosed |
| EP-0642516-A4 | MACROCYCLIC IMMUNOMODULATORS. | ABBOTT LAB (US) | 1994-06-15 | — | — | EP | disclosed |
| EP-0638082-A4 | MACROCYCLIC IMMUNOMODULATORS. | ABBOTT LAB (US) | 1994-06-09 | — | — | EP | disclosed |
| WO-1993004680-A1 | MACROCYCLIC IMMUNOMODULATORS | ABBOTT LABORATORIES (US) | 1993-03-18 | — | — | WO | disclosed |
| WO-1993004679-A1 | MACROCYCLIC IMMUNOMODULATORS | ABBOTT LABORATORIES (US) | 1993-03-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12285393-B2 | Roles of modulators of intersectin-Cdc42 signaling in Alzheimer's disease | CDC42, MDN1, HASPIN | CYP1A2 3914/4885LMNA 3251/4885PTGS2 3617/4885 |
| US-20260091009-A1 | ROLES OF MODULATORS OF INTERSECTIN-CDC42 SIGNALING IN ALZHEIMER'S DISEASE | CDC42, GAP43, HASPIN | CYP1A2 4150/4885LMNA 2076/4885PTGS2 3566/4885 |
| US-11713316-B2 | Substituted naphthyridinone compounds useful as T cell activators | DGKZ, DGKA, DGKG | CYP1A2 4133/4885LMNA 1862/4885PTGS2 2866/4885 |
| US-12595233-B2 | Thiosemicarbazates and uses thereof | TST, THRB, HSPB1 | CYP1A2 3031/4885LMNA 2788/4885PTGS2 4473/4885 |
| US-20230111252-A1 | THIOSEMICARBAZATES AND USES THEREOF | TST, ABAT, AADAC | CYP1A2 3108/4885LMNA 4387/4885PTGS2 4223/4885 |
| US-20230165815-A1 | ROLES OF MODULATORS OF INTERSECTIN-CDC42 SIGNALING IN ALZHEIMER?S DISEASE | CDC42, MDN1, GAP43 | CYP1A2 3879/4885LMNA 3241/4885PTGS2 3683/4885 |
| US-12600699-B2 | Thiosemicarbazates and uses thereof | MET, THRB, ABAT | CYP1A2 2469/4885LMNA 4184/4885PTGS2 3956/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.